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Abstract: 
According to REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals), testing for acute 
inhalation toxicity is required for chemicals manufactured or imported at tonnages ≥ 10 tons per year. 
Three OECD test guidelines for acute inhalation toxicity in vivo are adopted (TG 403, TG 436, and TG 433). 
Since animal testing is ethically, scientifically and economically questionable, adoption of alternative 
methods by the European Union and the OECD is needed. An in vitrosystem based on the study of lung 
surfactant function is introduced.  
In the European Union, the total number of animals used yearly for scientific purposes is over 11 million. 
Although it is 500,000 (4.5 %) less than in 2008, this figure remains too high. Toxicological and other safety 
evaluations account for 8.75 % or over 1 million animals annually(1). 
Between 2010 and 2015, 264 chemicals were tested for acute inhalation toxicity (data from echemportal.org) 
according to OECD Test Guidelines (TG) 403 (183 chemicals) and 436 (87 chemicals). Assuming that a study 
conducted according to TG 403 (LC50 protocol) requires 20 animals and that TG 436 uses 18 animals, nearly a 
thousand animals are subjected to acute inhalation toxicity studies annually in Europe. This number is solely 
for the testing of chemicals and do not take into account the testing of pharmaceuticals. 
According to REACH, testing for acute inhalation toxicity is required for chemicals manufactured or imported 
at tonnages ≥ 10 tons per year(2). Three OECD TG are adopted: TG 403 “Acute Inhalation Toxicity”, TG 436 
“Acute Inhalation Toxicity, Acute Toxic Class Method” and, since the 9th of October 2017, TG 433 “Acute 
Inhalation Toxicity, Fixed Dose Procedure”. For classification and labeling of substances and mixtures, it is 
recommended to use TG 433 or TG 436 rather than TG 403 as the two first have been adopted with reduction 
and refinement purposes(3). Further, TG 433 is based on evident clinical signs of toxicity, rather than death 
as an endpoint, as it is the case for TG 403 and 436(4). However, TG 403 may be necessary when regulatory 
needs cannot be satisfied with 433 and 436(3). Briefly, to assess acute inhalation toxicity according to these 
three guidelines, rats (or mice) are exposed nose-only for 4 hours to the test article  and observed for at least 
14 days after exposure(4–6). 
Using animals for toxicological evaluation does not come without challenges. Animal studies are costly and 
time consuming. As much as 3 to 5 kg of test article is required for testing(7). In addition, for a classic acute 
inhalation toxicity test, the experiment protocol has to be submitted for approval by the local ethics 
committee before the animals are bought and acclimatized prior to testing. Finally, after the 4-hour exposure, 
the animals are kept for observation for at least 14 days. The estimated turnaround time for carrying out the 
test is 3 to 4 months(7). Performing animal experiments requires qualified and experienced personnel, adding 
to the cost. Second, following Directive 2010/63/EU, “the methods selected should avoid, as far as possible, 
death as an end-point due to severe suffering experienced during the period before death”(8). The legislation 
in some countries, including Denmark, holds that death cannot be the endpoint of an experiment conducted 
on animals(9). Lastly, the relevance of using rats, or mice, to predict acute inhalation toxicity of a test article 
in humans is debatable. Lung physiology of rodents differs from humans in several ways. For example, the 
relative size of inhaled particles compared to the dimensions of the respiratory tract and the breathing 
frequency are very different in rats or mice compared to humans. 
Since animal testing is ethically, scientifically and economically questionable, adoption of alternative 
methods for acute inhalation toxicity by the European Union and the OECD is needed. 
After inhalation, any particle that is small enough will reach the deepest parts of the lungs, the alveolar 
region. On average, human lungs comprise 500 million alveoli, covering a total surface area of 70 m2. The 
epithelium of the alveoli is very thin to allow efficient oxygenation of the blood. A layer of liquid, the lung 
surfactant, covers the epithelium and is essential for breathing. One of its main functions is to reduce surface 
tension to near zero values in the lungs at the end of expiration. This prevents alveolar collapse and makes 
breathing effortless(10). Lung surfactant is the initial barrier that any inhaled substance meets. Our 
hypothesis is that lung surfactant is the first target of inhaled toxicants. Therefore we optimized an in vitro 
system centered around lung surfactant function monitoring for acute inhalation toxicity testing of inhaled 
substances(11). 
In the so-called constrained drop surfactometer, a drop of lung surfactant is deposited onto a sharp edge 
pedestal and exposed to the test article(12). A quartz crystal microbalance, placed next to the pedestal,  
estimates the mass of particles deposited onto the drop(11). The lung surfactant is compressed and 
expanded in cycles to imitate the surface area variations that occur during normal breathing. The frequency 
and degree of surface area compression are physiologically relevant. Images of the drop are captured during 
the exposure and analyzed using the axisymmetric drop shape analysis software to yield surface tensions 
over time(13). Unlike animal experiments, this innovative method is fast. Surface tension measurements can 
be obtained in real-time and the acute inhalation toxicity profile of a test article can be established within a 
few days. Moreover, a background in laboratory sciences and an initial training are enough to be able to 
perform experiments using this method. An additional advantage of the in vitro method is that it is much less 
expensive. A natural surfactant sold as a pharmaceutical under the name Curosurf® is used. On average, as 
little as 0.1 mL of LS at a concentration of 1 mg/mL (initial concentration of 80 mg/mL) is needed for toxicity 
testing of a test article, i.e. operating cost of about 0.07 €. 
In order to validate lung surfactant function inhibition as an in vitro assay for acute inhalation toxicity, 
standardization is essential. Improvements are necessary to increase key parameters such as sensitivity, 
specificity and reproducibility. Even though the system has great potential, it cannot stand alone. Rather it 
should be used in combination with other in vitro tests (e.g. cell-based cytotoxicity assays) to fully replace 
animals in acute inhalation toxicity testing. 
The method has already been successfully applied to impregnation products(14), inhaled medicines(11) and 
excipients for drug formulation (article in preparation). In one study comparing toxicity profiles of 21 
impregnation spray products in vitro and in vivo, a sensitivity of 100 % and a specificity of 63 % were found. 
The in vitro method could identify all the products that were toxic for mice to inhale and only three false 
positive were identified out of the 21 tested products. Furthermore, six of the products were involved in 
acute inhalation toxicity in humans after accidental inhalation. All of these six products inhibited lung 
surfactant function in vitro and were toxic to mice. Following the standardization of this method and its 
validation, industries (chemical, pharmaceutical and cosmetic industries and importers of chemicals ≥ 10 tons 
per year) will be able to assess acute inhalation toxicity in a fast, less expensive and ethically sound approach. 
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